Pathology results of risk‐reducing salpingo‐oophorectomy in <scp>BRCA1</scp>/2 carriers and long‐term clinical outcomes
In this large retrospective analysis of BRCA carriers who underwent RRSO, we confirmed that long-term follow-up is crucial for BRCA mutation carriers undergoing RRSO, as malignancies can still arise over time. In our study, the incidence of PPC was 1.5%, highlighting the need for extended surveillance. These findings underscore the importance of meticulous surgical protocols, expert pathology review, and ongoing monitoring to optimize patient outcomes.
Authors
- Meirav Schmidt
- Eiman Shalabna
- Ari Reiss
- Yakir Segev (ORCID: https://orcid.org/0000-0002-3483-5845)
- Chen Nahshon (ORCID: https://orcid.org/0000-0003-0786-6934)
- Wisam Assaf (ORCID: https://orcid.org/0000-0002-2866-9457)
- Yousef Abboud (ORCID: https://orcid.org/0000-0002-6149-0790)
- Ariel Zilberlicht (ORCID: https://orcid.org/0000-0001-7375-4514)
- Amalfi Qarawani
Institutions
- Technion – Israel Institute of Technology (IL)
- Emek Medical Center (IL)
- Rambam Health Care Campus (IL)
- Carmel Medical Center (IL)
Publication Details
- Journal
- International Journal of Gynecology & Obstetrics
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1002/ijgo.70110
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70